Sign inJoin waitlistJoin the waitlist

Michael Schweizer

Clinical Research Director, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · ·

History

Fred Hutch · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Johns Hopkins University School of Medicine
2011–2013
Internal Medicine
University of Chicago Medical Center
2008–2011
Temple University School of Medicine
2004–2008

Research

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Cancer Cell · 2017 · 633 citations
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
Journal of Clinical Investigation · 2019 · 388 citations
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study
Science Translational Medicine · 2015 · First of 13 authors · Corresponding · 217 citations

Evan Yu
57 papers
Peter Nelson
56 papers
Robert Montgomery
54 papers
Heather Cheng
45 papers
Emmanuel Antonarakis
26 papers
Petros Grivas
26 papers
Colin Pritchard
23 papers
Michael Haffner
23 papers · 3 as a fellow
Andrew Hsieh
22 papers
Todd Yezefski
22 papers
Laura Graham
20 papers · 2 as a fellow
Daniel Lin
19 papers

Grants

Augmenting PSMA Expression to Enhance PSMA Directed Therapeutic Efficacy
National Cancer Institute · R37
PI · $2.1M · Fred Hutchinson Cancer Center
2024–2029

Clinical trials

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
Principal investigator · Not yet recruiting · Phase 2
Fred Hutchinson Cancer Center
2026–2029
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Principal investigator · Recruiting · Phase 2
University of Washington
2026–2029
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Principal investigator · Withdrawn · Phase 1
Fred Hutchinson Cancer Center
2025–2028
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Principal investigator · Recruiting · Phase 2
Fred Hutchinson Cancer Center
2024–2027